

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. – 61. (Cancelled)

62. (Allowed) An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:36.

63. (Currently amended) An isolated polypeptide comprising a variant of the amino sequence of SEQ ID NO: 36, The polypeptide of claim 62, wherein the amino acid sequence of the variant of (b) has at least 90% identity to at least one of the sequences in (a) the amino acid sequence of SEQ ID NO: 36, and wherein the variant has superantigen (SAg) activity.

64. (Currently amended) An isolated polypeptide comprising a variant of the amino sequence of SEQ ID NO: 36, The polypeptide of claim 62, wherein the amino acid sequence of the variant of (b) has at least 95% identity to at least one of the sequences in (a) the amino acid sequence of SEQ ID NO: 36, and wherein the variant has superantigen (SAg) activity.

65. (Currently amended) An isolated polypeptide comprising a variant of the amino sequence of SEQ ID NO: 36, The polypeptide of claim 62, wherein the amino acid sequence of the variant comprises a conservative amino acid substitution, and wherein the variant has superantigen (SAg) activity.

66. – 72 (Cancelled)

73. (Allowed) A composition comprising the polypeptide of claim 62 and a pharmaceutically-acceptable carrier.

74. – 77. (Cancelled)

78. (Allowed) An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:40.

SM
79. (Allowed) An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:41